Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study

AIMS: Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD‐PAH) after defect correction have a poor prognosis compared with other CHD‐PAH patients. Therefore, it is important that these patients are treated as early and effectively as possible. Evidence support...

Descripción completa

Detalles Bibliográficos
Autores principales: Beghetti, Maurice, Channick, Richard N., Chin, Kelly M., Di Scala, Lilla, Gaine, Sean, Ghofrani, Hossein‐Ardeschir, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie V., Preiss, Ralph, Rubin, Lewis J., Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F., Galiè, Nazzareno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2019
Materias:
Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607487/
https://www.ncbi.nlm.nih.gov/pubmed/30632656
http://dx.doi.org/10.1002/ejhf.1375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607487/
https://www.ncbi.nlm.nih.gov/pubmed/30632656
http://dx.doi.org/10.1002/ejhf.1375

Ejemplares similares